Table 2.
Clinical trials for novel PARP and PARG inhibitors: monotherapy and combination therapy
| Target | Agent | Intervention | Cancer type | Phase | Clinicaltrials.gov identifier |
|---|---|---|---|---|---|
| PARP | Veliparib | Veliparib + Carboplatin | TNBC | III | NCT02032277 |
| Veliparib + Carboplatin + Paclitaxel vs CTx | NSCLC | III | NCT02264990 | ||
| Veliparib + Carboplatin + Paclitaxel | HER2- BRCA1/2m breast cancer | III | NCT02163694 | ||
| Veliparib + Carboplatin + Paclitaxel | Ovarian cancer | III | NCT02470585 | ||
| Veliparib + Carboplatin + Paclitaxel | NSCLC | III | NCT02106546 | ||
| Veliparib + Temozolomide | Glioblastoma | II/III | NCT02152982 | ||
| Veliparib + Temozolomide | Breast cancer | II | NCT01009788 | ||
| Veliparib + Temozolomide | CRC | II | NCT01051596 | ||
| Veliparib + Temozolomide | Solid tumors | II | NCT01193140 | ||
| Veliparib + Temozolomide | Melanoma | II | NCT00804908 | ||
| Veliparib ± Temozolomide | SCLC | II | NCT01638546 | ||
| Veliparib + RT + Temozolomide | Glioma without H3 K27M or BRAFV600 mutations | II | NCT03581292 | ||
| Veliparib + Temozolomide/Carboplatin + Paclitaxel | BRCA1/2m breast cancer | II | NCT01506609 | ||
| Veliparib + Temozolomide vs Pegylated Liposomal Doxorubicin | Ovarian cancer | II | NCT01113957 | ||
| Veliparib + Gemcitabine + Carboplatin | Testicular germ cell cancer | II | NCT02860819 | ||
| Veliparib + Cyclophosphamide | BRCA1/2m breast, ovarian, primary peritoneal or fallopian tube cancer, TNBC or low-grade NHL | II | NCT01306032 | ||
| Veliparib | Ovarian, fallopian tube or primary peritoneal cancer | II | NCT01540565 | ||
| Veliparib ± Carboplatin ± Paclitaxel | NSCLC | II | NCT01560104 | ||
| Topotecan + Carboplatin ± Veliparib | Advanced myeloproliferative disorders, AML or CML | II | NCT03289910 | ||
| Veliparib ± whole brain RT | NSCLC with brain metastases | II | NCT01657799 | ||
| Veliparib ± Cisplatin | TNBC, BRCA1/2m breast cancer ± brain metastases | II | NCT02595905 | ||
| Veliparib ± FOLFIRI ± Bevacizumab | CRC | II | NCT02305758 | ||
| Veliparib + Temozolomide | Solid tumors | II | NCT01827384 | ||
| Abiraterone + Prednisone ± Veliparib | CRPC | II | NCT01576172 | ||
| Veliparib + Topotecan + Filgrastim | Cervical cancer | II | NCT01266447 | ||
| Veliparib ± Gemcitabine and Cisplatin | Pancreatic cancer | II | NCT01585805 | ||
| Veliparib ± FOLFIRI | Pancreatic cancer | II | NCT02890355 | ||
| Veliparib ± Carboplatin | Breast cancer | II | NCT01149083 | ||
| Veliparib + FOLFOX + RT ± Pembrolizumab | Rectal cancer | II | NCT02921256 | ||
| Veliparib | Breast cancer | II | NCT01042379 | ||
| Senaparib | Senaparib (MT) | Ovarian cancer | III | NCT04169997 | |
| Senaparib | BRCA1/2m recurrent PtS ovarian cancer | II | NCT04089189 | ||
| Senaparib | HRR-mutated CRPC | II | NCT04822961 | ||
| Senaparib + Temozolomide | Advanced solid tumors and SCLC | I/II | NCT04434482 | ||
| Venadaparib | Venadaparib + XELOX/Irinotecan | Gastric cancer | I/II | NCT04725994 | |
| Venadaparib | HRD solid tumors | I/II | NCT04174716 | ||
| Stenoparib | Stenoparib | Ovarian cancer | II | NCT03878849 | |
| Stenoparib | Breast cancer | II | NCT03562832 | ||
| Stenoparib + Temozolomide/Carboplatin + Paclitaxel | Solid tumors and B-cell malignancies | I/II | NCT01618136 | ||
| Saruparib | Saruparib ± Durvalumab | SCLC | II | NCT06769126 | |
| Saruparib + AZD5335 | Solid tumors | I/II | NCT05797168 | ||
| Saruparib + AZD8205 | Solid tumors | I/II | NCT05123482 | ||
| Saruparib + Ceralasertib | Solid tumors | I/II | NCT02264678 | ||
| AZD9574 | AZD9574 ± Temozolomide/Deruxtecan | Solid tumors | I/II | NCT05417594 | |
| SC10914 | SC10914 | Breast cancer | II | NCT04556292 | |
| SC10914 | Ovarian cancer | II | NCT04556539 | ||
| SC10914 | BRCA1/2m CRPC | I/II | NCT04486937 | ||
| SC10914 | Solid tumors | I | NCT02940132 | ||
| Nesuparib | Nesuparib | Ovarian cancer | II | NCT05475184 | |
| Nesuparib + FOLFIRINOX/Gemcitabine + Paclitaxel | Pancreatic ductal adenocarcinoma | I | NCT05257993 | ||
| Nesuparib | Solid tumors | I | NCT04335604 | ||
| TSL-1502 | TSL-1502 vs CTx | BRCA1/2m breast cancer | II | NCT05420779 | |
| AMXI-5001 | AMXI-5001 | Solid tumors | I/II | NCT04503265 | |
| NMS-03305293 | NMS-03305293 + Temozolomide | Glioblastoma | I/II | NCT04910022 | |
| Simmiparib | Simmiparib | Solid tumors | I | NCT02993913 | |
| RP12146 | RP12146 | Solid tumors | I | NCT05002868 | |
| HWH340 | HWH340 | Solid tumors | I | NCT03415659 | |
| TQB3823 | TQB3823 | Solid tumors | I | NCT05021367 | |
| ABT-767 | ABT-767 | BRCA1/2m ovarian, fallopian tube or primary peritoneal cancer | I | NCT01339650 | |
| PARG | IDE161 | IDE161 | Advanced solid tumors | I | NCT05787587 |
| ETX-19477 | ETX-19477 ± Pembrolizumab | Advanced solid tumors | I | NCT06395519 |
Data extracted from clinicaltrials.gov up until November 2025